Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) potently induces apoptosis in most cancer cells, but not in normal cells, and, thus, has attracted intense interest as a promising antitumor agent. Activity-guided fractionation of the culture broth of the actinomycete CKK1172 strain led to the isolation of the antibiotic resistomycin (1) using human gastric adenocarcinoma AGS cells. Compound 1 exhibited TRAIL resistance-overcoming activity at 2 μM with 38% more inhibition than a treatment with 1 alone (without TRAIL) in TRAIL-resistant AGS cells.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a potent and selective inducer of apoptosis in tumor cells, but not in normal cells, which makes it an attractive target for the development of new cancer therapy [1] . TRAIL is expressed on the membranes of immune cells and binds transmembrane receptors such as the death receptors, DR4 (TRAIL-R1) and DR5 (TRAIL-R2), which have a cytoplasmic death domain that transmits apoptotic signals into cells. There are two essential apoptotic pathways, referred to as the death receptor (extrinsic) pathway and mitochondrial (intrinsic) pathway. TRAIL may activate either pathway depending on the cell type. TRAIL-induced apoptosis is initiated after the binding of TRAIL to the death receptors (DR4 and DR5). Death receptors then homotrimerize and death signals are transmitted to the cytoplasm, enabling the recruitment of the adaptor protein Fas-associated death domain (FADD), deathinducing signaling complex (DISC) formation, the proteolytic activation of caspase-8, and, consequently, the activation of caspase-3, which induces apoptosis. Proteolytic activated caspase-8 further activates Bid, which, in turn, translocates to the mitochondria and activates mitochondrial pathways.
However, a large number of cancer cells, particularly some highly malignant tumors, are resistant to the induction of apoptosis by TRAIL [2] . For example, lung, breast, prostate, and gastric cancers are resistant to TRAIL. TRAIL resistance may occur at different points in the signaling pathways of TRAIL-induced apoptosis. Decreases in the expression of the death receptors DR4 and DR5 due to mutations may lead to TRAIL resistance, and defects in any of the essential molecules, such as FADD or caspase-8, in the formation of DISC may result in TRAIL resistance. Therefore, overcoming TRAIL resistance and understanding the mechanisms responsible for the development of resistance are very important in anticancer drug discovery.
A number of natural products have recently been reported to exhibit TRAIL resistance-overcoming activity including luteolin, curcumin, resveratrol, and apigenin [3] . Our research group has also isolated several compounds exhibiting TRAIL resistance-overcoming activity, such as fuligocandin B, parviflorene F, 1-Oformylrocagloic acid, cryptolepine, scopadulciol, pannokin D, and artonin E [4] . In the course of our screening program for bioactive natural products, we isolated actinomycetes strains from soil and marine samples collected in various areas of Japan in order to construct an in-house strain library [5] . Approximately 90 of these strains were initially used for cytotoxicity-based screening against human gastric adenocarcinoma (AGS) cell lines. Strains that were positive in the cytotoxicity test were then examined in a second screening for TRAIL resistance-overcoming activity and an LC-MS analysis. Among the extracts of strains exhibiting TRAIL resistance-overcoming activity in AGS cells, those containing nonactin-related compounds [6] detected in the LC-MS analysis were excluded from further study, and this resulted in the selection of the strain CKK1172 as a hit sample.
The strain CKK1172 was isolated from a soil sample collected at Onjuku beach, Chiba Prefecture, Japan, and the MeOH-soluble fraction of the cultured broth of this strain exhibited 51% cell viability at 10 μg/mL in our first screening. A small-scale culture using liquid Waksman media (100 mL) was prepared, and the EtOAc extract of the supernatant of the culture broth exhibited TRAIL resistance-overcoming activity in the second screening. A large-scale culture using liquid Waksman media (11.2 L) with shaking at 28 °C for 5 days was separated into a supernatant and mycelia by centrifugation. The EtOAc-soluble fraction of the supernatant of the culture was subjected to silica gel and ODS column chromatography, followed by preparative ODS HPLC to provide resistomycin (1, ESIMS m/z 377 [M+H] + ) (Figure 1 ), which was identified by comparisons with published spectral data [7, 8] . The occurrence of resistomycin (1) was previously reported from culture broths of several kinds of actinomycetes [7] [8] [9] [10] .
The AGS cell line is known to be resistant to TRAIL [11] . As shown in Figure 2 , the treatment of an AGS cell line with 100 ng/mL of TRAIL for 24 hours resulted in only a slight decrease in cell viability, while luteolin [12] at 17.5 μM, which was used a positive control, was 50% more potent when administered in combination with TRAIL than when administered alone. TRAIL (100 ng/mL) led to cell viability being 38% lower than that with the compound alone (without TRAIL), which confirmed the potent ability of compound 1 to overcome TRAIL resistance. TRAIL is expected as a potential cancer therapeutic agent, because of its selective effect toward tumor cells. Understanding the mechanism of TRAIL-resistance is important for developing strategies of successful use of TRAIL. Combined treatment with chemotherapeutic agents, including natural products, may be a promising approach to overcome such resistance and enhance the therapeutic potential of TRAIL. In the present study, the bioassayguided separation of an extract of the cultured media of the actinomycete strain CKK1172 led to the isolation of resistomycin (1). The antimicrobial and cytotoxic activities of 1 were described previously [8] , while we herein reported the TRAIL resistanceovercoming activity of 1 at 2 µM in AGS cells for the first time, thereby suggesting their possible use in combination with TRAIL against AGS cells.
Experimental
General: NMR, JEOL ECP 400 and ECP 600 spectrometers; ESIMS, JEOL JMS-T100LP mass spectrometer.
Microbial strain and fermentation: Strain CKK1172 was separated on humic acid-vitamin (HV) agar [13] , a medium for the selective isolation of actinomycetes, from a soil sample collected at Onjuku beach, Chiba Prefecture, Japan, according to previously described procedures [14] . The spores of this strain were kept in a freezer in 15% glycerol solution, grown on solid Waksman medium containing agar for 5-7 days, transferred to a flask (500 mL), and inoculated into 100 mL of Waksman medium consisting of glucose (2 g/100 mL), meat extract (0.5 g/100 mL), peptone (0.5 g/100 mL), dried yeast (0.3 g/100 mL), NaCl (0.5 g/100 mL), and CaCO 3 (0.3 g/100 mL). The mixture was then cultured at 28 °C for 5 days on a reciprocating shaker. The seed culture (20 mL) was transferred into 16 flasks (3 L) containing 700 mL of liquid Waksman medium and cultured at 28 °C for 5 days on the reciprocating shaker.
Extraction and Isolation:
The culture broth (11.2 L in total) of the CKK1172 strain was harvested and centrifuged (3000 rpm, 20 min) to separate the supernatant and mycelia. The supernatant was extracted with EtOAc (500 mL × 3) to obtain the EtOAc-soluble fraction (2.2 g). The EtOAc-soluble fraction of the supernatant was subjected to silica gel column chromatography (40 × 160 mm) eluted stepwise with . They were then incubated at 37 °C for 24 h in a 5% CO 2 incubator. Test samples at different doses with or without TRAIL (100 ng/mL) were added to each well and incubated for 24 h. They were treated with fluorescein diacetate (Wako) in PBS buffer (10 μg/mL), and fluorescein was detected in a 1-h incubation [15] . Assays were performed at least in triplicate. IC 50 values were calculated by a probit analysis. 
